CellerateRX® Added to List of Preferred Products for Golden Living Healthcare Network

FORT WORTH, Texas, Dec. 12, 2011 /PRNewswire/ -- Wound Management Technologies, Inc., (OTCQB: WNDM | WNDM.PK) a leading innovator in advanced wound care solutions, today announced that Fort Smith, AR based Golden Living has added CellerateRX® to its formulary and is now on the list of preferred products approved for use within its healthcare network. Golden Living, one of the country's premiere integrated healthcare service companies, provides services for the elderly and disabled including nursing home care, rehabilitation therapy, hospice care, home health services and temporary staffing services. The company employs more than 40,000 and has in its care about 30,000 patients daily.

"Being added to the formulary list at Golden Living is an important imprimatur for CellerateRX.  Our flagship product will now be a choice in their over 300 Living Centers including skilled nursing locations, as well as in their 68 hospice and home health locations.  With our acquisition of Juventas LLC and its established sales force, we will be able to educate and establish sales quickly at each Golden Living Facility," said Bryant Gaines, Chief Operating Officer of Wound Management Technologies.  He further stated, "The agreement is part of our long-term plan to penetrate the professional healthcare markets worldwide.  The Company expects to sign additional agreements with major healthcare system clients that will further establish CellerateRX® as a leading product in the area of wound management."

"We are very excited about the opportunity to work with the Golden Living facilities," said Cathy Bradshaw, President of WNDM subsidiary Wound Care Innovations.  "CellerateRX® is FDA cleared for use on all acute and chronic wounds except for 3rd degree burns and has been show to provide quality outcomes in a cost effective manner.  This is essential for healthcare providers."

About Wound Management Technologies, Inc.
Wound Management Technologies, Inc. is an emerging commercial stage company with its primary products in the $5B worldwide advanced wound care market. Wound Management's primary focus is the distribution of its unique, patented collagen product, CellerateRX®, which is FDA cleared and reimbursable under Medicare Part B. Wound Management has other advanced biotech products in development including a patented resorbable bone wax line that is in late stages of development, as well as a subsidiary focused on technology for secure healthcare data collaboration and storage.  More information can be found on the company's web sites: http://www.wmgtech.com and http://www.celleraterx.com.

Follow us on: FACEBOOK | TWITTER | LINKEDIN

About Golden Living, Inc:
Golden Living is a family of companies that specialize in recovery care. Its mission is to help people recover health and improve quality of life through a network of healthcare services, including rehab, home care, assisted living, skilled nursing care and hospice. The Golden Living family of companies include Golden LivingCenters, Aegis Therapies, AseraCare Hospice and Home Health, and 360 Healthcare Staffing. There are more than 300 Golden LivingCenters in 21 states. Golden Living also offers assisted living services at more than 40 locations. In addition, the Golden Innovations companies partner with more than 1,000 nursing homes, hospitals and other health care organizations in 37 states and the District of Columbia. Collectively, the Golden Living family of companies has more than 42,000 employees who provide quality healthcare to more than 60,000 patients every day. More information can be found on the company's web sites: http://www.goldenliving.com 

Safe Harbor Statement:
The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development and any other statements not constituting historical facts are "forward-looking statements," within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company's SEC filings, which could cause the company's actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.

For Wound Management Technologies Shareholder Information please call (917) 974-9872 or visit http://www.wmgtech.com

SOURCE Wound Management Technologies, Inc.